KU ASH 2018 Review: Current Updates in Hematologic Diseases
Avatar

ASH December 2018- Lymphoma - Efficacy and Safety from ZUMA 1, JULIET and Other Top Trials

By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Frederick L. Locke
By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Frederick L. Locke
373 views
March 19, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
08:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…

Feat. R. Bansal
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
09:45
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …

Feat. M. Kamdar
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

The Improbable History of CAR T-Cells

Feat. C. June
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

10:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Rates of CRS and ICANS From CIBMTR Data o…

Feat. J. DiPersio
25:44
Tara Graff

DLBCL Updates From iCML 2023

06:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes of Pts With Richter's Transfo…

Feat. A. Kittai
07:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune
05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips